Scarica l'app Stockscreener
2.63
14.35%
0.33
Dopo l'orario di chiusura:
2.54
-0.09
-3.42%
Heartbeam Inc Borsa (BEAT) Ultime notizie
HeartBeam shares skyrocket after FDA signs off on 12-lead ECG synthesis software - MSN
HeartBeam Stock 7-Day Winning Spree: Stock Climbs 227% - Trefis
Heartbeam Inc. (BEAT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
HeartBeam Shares Skyrocket: FDA Boost - timothysykes.com
HeartBeam Soars with FDA Approval for Breakthrough ECG Technology - timothysykes.com
HeartBeam Stock Soars: Should You Buy? - timothysykes.com
Heartbeam stock is a buy, this analyst says - Cantech Letter
HeartBeam Stock Surges 201%, With A 6-Day Winning Spree - Trefis
Benchmark Upgrades HeartBeam (BEAT) - Nasdaq
BEAT Secures FDA Nod for First Cable-Free At-Home 12-Lead ECG System - sharewise.com
HeartBeam updates regulatory strategy for 12-lead ECG Synthesis Software - MSN
HeartBeam Stock Surges: Analyzing the Uptrend - StocksToTrade
Why Is Micro Cap HeartBeam Stock Surging On Wednesday? - Sahm
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
HeartBeam swells on turning FDA rejection into ECG clearance - Fierce Biotech
symbol__ Stock Quote Price and Forecast - CNN
3 Penny Stocks to Watch Now, 12/11/25 - TipRanks
Why did BEAT stock rocket 72% in pre-market today? - MSN
HeartBeam receives US FDA clearance for at-home arrhythmia assessment with cable-free 12-lead ECG - Cardiac Rhythm News
HeartBeam (BEAT) Receives Upgrade from Benchmark Analyst | BEAT Stock News - GuruFocus
HeartBeam go-to-market strategy remains on track, says Benchmark - TipRanks
HeartBeam stock soars as H.C. Wainwright doubles price target on FDA clearance - Investing.com India
HeartBeam sinks after ‘Not Substantially Equivalent’ letter from FDA - MSN
HeartBeam (BEAT) Stock Soars After FDA Clearance: Latest News, Forecasts and Analyst Views - ts2.tech
Most Active U.S. Stocks Today: HeartBeam, Nvidia, Tesla, Netflix and Nextdoor Lead Volatile Trade (Dec. 11, 2025) - ts2.tech
5-Day Rally Sends HeartBeam Stock Up 120% - Trefis
HeartBeam Receives FDA Clearance for 12-Lead ECG Synthesis Software Following Appeal - citybuzz
HeartBeam announces FDA clearance for 12-lead ECG synthesis software - MSN
Oracle, Synopsys, Heartbeam, Planet Labs And Adobe: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
HC Wainwright & Co. Maintains HeartBeam (BEAT) Buy Recommendation - Nasdaq
Heartbeam wins appeal, gains FDA clearance - BioWorld MedTech
FDA Greenlight Sends HeartBeam, Photronics, And Designer Brands Shares Climbing - Finimize
HeartBeam (BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal - Yahoo Finance
HeartBeam’s Leap: Should Investors Be Wary? - StocksToTrade
FDA Clears HeartBeam Cable-free 12-lead ECG - respiratory-therapy.com
HeartBeam Secures FDA Clearance for 12-Lead ECG Synthesis Software Following Appeal - citybuzz
HeartBeam (BEAT) Stock: Surges 50% After FDA Grants Clearance For its 12-lead ECG Device - parameter.io
HeartBeam (BEAT) Analyst Rating: HC Wainwright Raises Price Targ - GuruFocus
HeartBeam price target raised to $5.50 from $2.50 at H.C. Wainwright - TipRanks
FDA clears HeartBeam’s at-home arrhythmia assessment tool - Yahoo
Weekly Trades: Is HeartBeam Inc stock recession proofTrade Entry Report & Community Trade Idea Sharing Platform - BỘ NỘI VỤ
HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal - TipRanks
HeartBeam Receives FDA Clearance for 12-Lead ECG for At-Home Arrhythmia Assessment - marketscreener.com
HeartBeam Wins FDA Nod for Cable-Free 12-Lead ECG for Home Arrhythmia Assessment - Medical Product Outsourcing
HeartBeam Shares Surge: Buy Signal? - timothysykes.com
HeartBeam : Earnings Documents - marketscreener.com
HeartBeam stock soars after FDA clearance for 12-lead ECG synthesis software - Investing.com Nigeria
Why Is HeartBeam Stock (BEAT) Up Today? - TipRanks
Heartbeam rises after FDA clears its cable‑free ECG software - TradingView — Track All Markets
HeartBeam’s 12-lead ECG synthesis software receives FDA clearance By Investing.com - Investing.com Australia
HeartBeam’s 12-lead ECG synthesis software receives FDA clearance - Investing.com India
HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment - Business Wire
Why Did BEAT Stock Rocket 72% In Pre-Market Today? - Stocktwits
Heartbeam, Inc.Common Stock (Nasdaq:BEAT) Stock Quote - Markets Financial Content
HeartBeam, Inc. Earnings Call Highlights Progress and Challenges - MSN
HC Wainwright & Co. Initiates Coverage of HeartBeam (BEAT) with Buy Recommendation - Nasdaq
An analyst sees good growth prospects for HeartBeam Inc (BEAT) - Setenews
HeartBeam (BEAT) Receives 'Buy' Rating from HC Wainwright & Co. - GuruFocus
1.94%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):